^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Published date:
09/21/2020
Excerpt:
This study (NCT01260181) was a phase II, non-randomized, open-label study to evaluate the anti-tumoral activity of erlotinib in patients with locally advanced or metastatic NSCLC with EGFR activating mutations….Median disease duration was 1 month (0–32 months) and histology for 96.7% of patients was adenocarcinoma....For exon 19 patients, the median PFS was 14.4 months (95% CI: 4.2–41.8) and for exon 21 9.8 months (95% CI: 3.8–13.5).
DOI:
10.1016/j.pulmoe.2020.08.007
Trial ID:
